Neurocrine Biosciences (NBIX) 'Buy' Rating Intact at Jefferies Despite Setback

September 10, 2013 7:12 AM EDT
Get Alerts NBIX Hot Sheet
Price: $41.27 -0.84%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade NBIX Now!
Join SI Premium – FREE
Jefferies Thomas Wei defended Neurocrine Biosciences (NASDAQ: NBIX) after the company's VMAT2 inhibitor NBI-98854 failed to show a significant improvement at 50 mg over placebo in its primary endpoint of AIMS assessment at week 6 in its Phase 2b Kinect Trial in tardive dyskinesia, a form of movement disorder.

"The data suggest that higher doses of '854 of 100mg or higher could safely improve efficacy, although the Kinect failure raises the risk profile around the drug. ‘854 remains upside to our valuation," Wei said.

The firm maintained a Buy rating and price target of $16.00.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $16.70 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co, Thomas Wei

Add Your Comment